Revenue RoundUp Newsletter

Dimitris Adamidis

Vice President of RevOps | Head of RevOps | Chief Operating Officer | SaaS | Head of Operations | FP&A | Data & Analytics | Operational Excellence | Restructuring | SalesTech

Published Jul 24, 2024

📚 "The Future of Hybrid GTM Strategies. Why Combining PLG and Sales-Led Approaches is Inevitable Future of GTM?" Read the full article on RevOps Venture. #gtm #sales #revops

GTM strategies continue to evolve, with companies increasingly adopting hybrid approaches that combine Product-Led Growth (PLG) and traditional sales-led methods. This shift accelerates with the #ai by changing customer expectations and needing a more personalized and conversational approach. Here are the key takeaways from the article:

Trend Towards PLG Adoption: Product-Led Growth (PLG) is not a new concept, but it has been gaining dominance in the tech space. According to OpenView’s 2022 Product Benchmarks Report, the adoption of PLG has increased by 20% over the last three years.
Changing Customer Expectations: Nearly 80% of customers expect a unique and personalized approach from their vendors and service providers, driving the demand for immediate value creation.
Challenges in Transition: The article highlights several challenges in transitioning to a hybrid PLG and sales-led approach, including cultural shifts, resource reallocation, measurement challenges, and balancing short-term results with long-term strategy.

🎧 Latest RevTech Podcast Episodes #podcast

Reply automates sales prospecting, outreach, and lead generation for small and medium businesses, adopting the power of AI to revolutionize these tasks. The platform covers a wide range of use cases, from suggesting ideal customer profiles and crafting personalized messages and multi-channel sequences to responding to prospect emails on behalf of users and converting website traffic into leads. Reply ensures a consistent flow of leads by seamlessly integrating outbound and inbound channels.

Link: Enhancing Sales Efficiency with Reply.io

LeanData Christine Maxey Hendrick Lee are the market-leading revenue orchestration platform designed to enhance the efficiency of customers' CRM, sales, and marketing technologies for B2B revenue teams. Their mission revolves around harmonizing people, processes, and technology through agile scheduling and workflow automation, enabling businesses to adapt and optimize their revenue operations. LeanData's origin story started when co-founder Evan Liang, a seasoned product professional, faced challenges in aligning marketing and sales while launching a product in a previous role. Struggling with data messiness and inefficiencies, co-founders envisioned a solution that could seamlessly integrate and streamline go-to-market processes. Listen to the entire conversation.

Link: Harmonizing Growth: LeanData's Revenue Solutions

Warmly, | maximus greenwald is revolutionizing lead generation by providing warm leads that significantly enhance your sales pipeline. The company aims to use AI to identify potential customers interested in related topics but have yet to discover your business. By analyzing web searches and de-anonymizing website traffic, Warmly finds and ranks the best leads for you, reaching out automatically via emails, LinkedIn messages, chat, and, soon, voicemails. This innovative approach yields a 3x higher conversion rate than traditional cold leads and automates SDR's outreach at 5-6x of the average role volume.

Link: Warmly.ai Wonders: AI Meets Business Brilliance

⭐️ Top 5 Funding Rounds - last week with $1M+/ US HQ #investment

Last week, we had a total of $1.63B invested across 58 companies, highlighting a strong investor focus on industries such as Biotechnology (4), Artificial Intelligence (4), Health Care (3), Financial Services (2), and Robotics (1). The largest investments included Cardurion Pharmaceuticals, with $260.0M for innovative cardiovascular therapies; Saronic, with $175.0M for AI-driven manufacturing and robotics solutions; and Scorpion Therapeutics, with $150.0M for cancer treatment research. Additional significant investments were Aven's $142.0M for financial applications and services and NGM Biopharmaceuticals' $122.0M for biopharmaceutical research, showcasing the diversity and potential in tech-driven and health-related sectors.

Here are the top 5 investments based on the Funding Amounts from last week:

Cardurion Pharmaceuticals | $260M | Fidelity, Blue Owl, Takeda, Google Ventures, Invus Summary: Cardurion Pharmaceuticals is focused on developing innovative cardiovascular therapies to address unmet medical needs. Their cutting-edge research and commitment to improving heart health have attracted substantial funding.

Saronic Technologies | $175M | Andreessen Horowitz, Lightspeed Venture Partners, General Catalyst, Coatue, GV

Summary: Saronic designs and manufactures unmanned surface vehicles and robotic solutions. Their innovative approach to AI-driven manufacturing and robotics has positioned them as a leader.

Scorpion Therapeutics | $150M | Fidelity, Lightspeed Venture Partners, Invus, Google Ventures, Arch Venture Partners

Summary: Scorpion Therapeutics is a clinical-stage oncology company that focuses on cancer treatment research and development. Its work in advancing cancer therapies has garnered significant investment.

Aven | $142M | Khosla Ventures, General Catalyst, Founders Fund, Index Ventures, Ribbit Capital

Summary: Aven is dedicated to inventing new ways to save people money through innovative financial applications and services. Their unique solutions in the financial sector have secured major funding.

NGM Biopharmaceuticals | $122M | Merck, The Column Group, Greenspring Associates, Topspin Partners, Nextech Invest

Summary: NGM Biopharmaceuticals is a drug discovery company focusing on genetics and medical applications. Their biopharmaceutical research aims to develop new treatments for various medical conditions, attracting substantial investment.